Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TXN
3. NOW
4. TSLA
5. GOOG
6. IBM
7. KNX
8. CSX
9. LVS
10. INTC

Go back to Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
(NASDAQ: MDCX) Delayed: 0.37 --0 (-0%)
Previous Close $0.37    52 Week High $ 
Open $0.37    52 Week Low $ 
Day High $0.37    P/E N/A 
Day Low $0.37    EPS $ 
Volume 24,688       

(NASDAQ: MDCX) Delayed: 0.37 --0 (-0%)
Previous Close $0.37    52 Week High $ 
Open $0.37    52 Week Low $ 
Day High $0.37    P/E N/A 
Day Low $0.37    EPS $ 
Volume 24,688